 BASEL, Switzerland, March 29, 2021 GLOBE NEWSWIRE -- Myovant Sciences NYSE: MYOV, a healthcare company focused on redefining care for women and for men, today announced the European Medicines Agency EMA has validated the Marketing Authorization Application MAA for relugolix for the treatment of advanced prostate cancer. The validation of the application confirms the submission is sufficiently complete for the EMA to begin the formal review process. 